Photo by Skoch3 via Wikimedia Commons People with congenital ichthyosis, the group of rare inherited disorders that impair the skin barrier, may face a substantially increased risk of food allergy, allergic rhinitis, and allergic asthma, according to a new study published in the Journal of Allergy and Clinical Immunology. The cross-sectional survey by researchers at Northwestern University in Chicago included 115 children and adults with physician-confirmed congenital ichthyo

Photo by Eisfelder via Wikimedia Commons New research has documented a significant impact of severe atopic dermatitis (AD) on a child’s height, and that dupilumab treatment can help improve growth. The study, published in the Journal of the American Academy of Dermatology, investigated the effect of a medication commonly used to treat AD on growth and bone biomarkers in 123 children aged six to 11 years with severe eczema. Researchers found that children who had severe AD and

Oral antihistamines show little meaningful benefit for AD and can even increase the risk of cognitive impairment in some patients

GLP-1 receptor agonists may have potential applications as adjunct therapy for PsO, AD, HS, chronic wounds, and other skin conditions.

Trust levels regarding topical therapy were higher among AD patients than PsO patients

Patients with AD have an increased risk of retinal detachment and postoperative PVR.

Photo by James Heilman, MD via Wikimedia Commons New research shows that adults with atopic dermatitis (AD), particularly those with childhood onset, report significantly greater limitations in their educational and professional choices. Investigators found that up to 38% of childhood-onset patients reported career restrictions and more than 36% reporting constrained study choices, compared to individuals whose disease began in adulthood. The authors say their findings, publi

Staphylococcus aureus. Photo by Janice Haney Carr, provided by CDC/ Matthew J. Arduino, DRPH, via Wikimedia Commons New findings suggest that commensal bacteria on the skin release molecules that inhibit the skin’s production of pro-inflammatory interleukin (IL)-33, potentially preventing atopic dermatitis (AD) flares. Published in Nature Communications, the findings come from research conducted at the University of Manchester and Tokyo University of Agriculture and Technolog